Elisabeth H. Thijssen,Renaud La Joie,Amy Wolf,Amelia Strom,Ping Wang,Leonardo Iaccarino,Viktoriya Bourakova,Yann Cobigo,Hilary Heuer,Salvatore Spina,Lawren VandeVrede,Xiyun Chai,Nicholas K. Proctor,David C. Airey,Sergey Shcherbinin,Cynthia Duggan Evans,John R. Sims,Henrik Zetterberg,Kaj Blennow,Anna M. Karydas,Charlotte E. Teunissen,Joel H. Kramer,Lea T. Grinberg,William W. Seeley,Howie Rosen,Bradley F. Boeve,Bruce L. Miller,Gil D. Rabinovici,Jeffrey L. Dage,Julio C. Rojas,Adam L. Boxer,

Abstract:With the potential development of new disease-modifying Alzheimer's disease (AD) therapies, simple, widely available screening tests are needed to identify which individuals, who are experiencing symptoms of cognitive or behavioral decline, should be further evaluated for initiation of treatment. A blood-based test for AD would be a less invasive and less expensive screening tool than the currently approved cerebrospinal fluid or amyloid β positron emission tomography (PET) diagnostic tests. We examined whether plasma tau phosphorylated at residue 181 (pTau181) could differentiate between clinically diagnosed or autopsy-confirmed AD and frontotemporal lobar degeneration. Plasma pTau181 concentrations were increased by 3.5-fold in AD compared to controls and differentiated AD from both clinically diagnosed (receiver operating characteristic area under the curve of 0.894) and autopsy-confirmed frontotemporal lobar degeneration (area under the curve of 0.878). Plasma pTau181 identified individuals who were amyloid β-PET-positive regardless of clinical diagnosis and correlated with cortical tau protein deposition measured by <sup>18</sup>F-flortaucipir PET. Plasma pTau181 may be useful to screen for tau pathology associated with AD.

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration